Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Charlotte Gerd Hannibal"'
Autor:
Rasmus Hertzum-Larsen, Susanne K. Kjaer, Charlotte Gerd Hannibal, Christian Dehlendorff, Louise Baandrup
Publikováno v:
Gynecologic Oncology. 161:458-462
Objective To examine the influence of socioeconomic status (SES) on long-term survival of non-localized ovarian cancer. Methods All women in Denmark with a first diagnosis of non-localized epithelial ovarian cancer 1982–2007 were identified in the
Autor:
Robert J. Kurman, Kirsten Frederiksen, Russell Vang, Charlotte Gerd Hannibal, Susanne K. Kjaer
Publikováno v:
International Journal of Cancer. 147:990-995
Population-based evidence regarding risk of ovarian cancer after a borderline ovarian tumor (BOT) is sparse. We aimed to examine the incidence of specific types of ovarian cancer in women with serous or mucinous BOTs in a nationwide cohort study with
Autor:
Charlotte Gerd Hannibal, M. Herman Chui, Kirsten Frederiksen, Russell Vang, Ie Ming Shih, Tian Li Wang, Susanne K. Kjaer
Publikováno v:
Oncotarget
Ovarian serous borderline tumor (SBT) is a known precursor of low-grade serous carcinoma. While most SBTs are cured surgically, some progress to carcinoma and a risk predictor for malignant relapse is needed to ensure vigilant follow-up and additiona
Autor:
Ie Ming Shih, Tian Li Wang, Kirsten Frederiksen, Susanne K. Kjaer, Charlotte Gerd Hannibal, M. Herman Chui, Russell Vang
Publikováno v:
Oncotarget
Autor:
Felix Zeppernick, Ie Ming Shih, Yohan Suryo Rahmanto, Susanne K. Kjaer, Charlotte Gerd Hannibal, Deyin Xing, Russell Vang, Tian Li Wang
Publikováno v:
Human Pathology. 68:87-91
Activating mutations involving the members of the RAS signaling pathway, including KRAS, NRAS, and BRAF, have been reported in ovarian low-grade serous carcinoma and its precursor lesion, serous borderline tumor (SBT). Whether additional genetic alte
Autor:
Jette Junge, Robert J. Kurman, Susanne K. Kjaer, Charlotte Gerd Hannibal, Russell Vang, Kirsten Frederiksen
Publikováno v:
American Journal of Surgical Pathology. 41:725-737
Ovarian serous borderline tumors (SBTs) have been the subject of considerable controversy, particularly with regard to terminology and behavior. It has been proposed that they constitute a heterogenous group of tumors composed, for the most part, of
Autor:
Robert J. Kurman, Louise Baandrup, Charlotte Gerd Hannibal, Emma L. Kaderly Rasmussen, Russell Vang, Christian Dehlendorff, Jette Junge, Susanne K. Kjaer
Publikováno v:
Gynecologic Oncology. 144:571-576
Objective Few studies have examined the risk of an ovarian serous borderline tumor (SBT) associated with parity, infertility, oral contraceptives (OCs), or hormone replacement therapy (HRT), which was the study aim. Methods This nationwide case-contr
Autor:
Robert J. Kurman, Charlotte Gerd Hannibal, Russell Vang, Kirsten Frederiksen, Jette Junge, Susanne K. Kjaer
Publikováno v:
Gynecologic Oncology. 144:174-180
Objective Absolute risk and risk factors for recurrence and ovarian serous carcinoma following ovarian serous borderline tumors (SBTs) is not well-established. Methods We included all women with SBTs in Denmark, 1978–2002. Diagnoses were confirmed
Autor:
Felix Zeppernick, Susanne K. Kjaer, Kirsten Frederiksen, Zoe Q. Wang, Michael Herman Chui, Charlotte Gerd Hannibal, Tian Li Wang, Ie Ming Shih, Russell Vang, Leslie Cope, Robert J. Kurman, Deyin Xing
Publikováno v:
Am J Surg Pathol
Although risk factors have been established for development of serous carcinoma after a diagnosis of serous borderline tumor (SBT), comprising atypical proliferative serous tumor (APST) [i.e. conventional SBT] and non-invasive low-grade serous carcin
Publikováno v:
Acta Obstetricia et Gynecologica Scandinavica. 95:1181-1189
Introduction The Nordic countries are areas with a high-incidence of ovarian cancer; however, differences between the countries exist. Material and methods We used the Danish Cancer Registry to identify 11 264 cases of ovarian cancer and 363 cases of